Filing Flows › Nutra Pharma (NPHC) › Q2 2026
Nutra Pharma (NPHC) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 19, 2026
Nutra Pharma (NPHC) reported revenue of $34K for the second quarter 2026 (Q2 2026), -59% from a year earlier and +26% from the quarter before.
Nutra Pharma, Q2 2026: revenue $34K (-59% year over year), net loss $3.9M, operating cash flow −$251K. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $34K | +26% | -59% |
| Operating profit | −$435K | — | — |
| Net earnings | −$3.9M | — | -1168% |
| Operating cash flow | −$251K | — | — |
What changed
Revenue was $34K in Q2 2026, down 59% year over year and up 26% from the previous quarter.
Gross margin was 94.7%, up 19.6 points from Q2 2025. Operating costs exceeded revenue by $435K, an operating margin of -1263.6%. Operating expenses grew 32% against a revenue fall of 59%. The quarter ended with a net loss of $3.9M, wider than the previous quarter's $460K loss. Net interest and other expense of $3.5M was the main reason.
Operating cash flow was −$251K. Non-cash charges added back $2K of depreciation and $4K of share-based compensation. Working capital and other items added $3.7M.
Questions
What was Nutra Pharma's revenue in the second quarter 2026?
Nutra Pharma (NPHC) reported revenue of $34K for the second quarter 2026 (Q2 2026), -59% from a year earlier and +26% from the quarter before.
Source: Nutra Pharma 10-Q on SEC EDGAR.